immunotherapy

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical’s Clinical Research at 2025 Annual Meeting

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) -...

COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security SectorsWEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE)...

FACIT and OBIO® announce inaugural WeSEED cohort of women-led start-ups in joint seed capital and commercialization program

Program supports women entrepreneurs in life science who are driving the advancement of innovations and healthcare TORONTO, March 6, 2025...

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

 Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...

New York Blood Center Enterprises and Human Life CORD Sign Letter of Intent to Expand Manufacturing Collaboration for Umbilical Cord -Derived Mesenchymal Stromal Cells

This collaboration will expand Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a contract development...

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics’ Single Cell Genomics Sequencing Technology

Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand...

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100  in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA,...

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW...

error: Content is protected !!